Frazier Management’s Sutro Biopharma STRO Stock Holding History

Frazier Management’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-177,648	Closed	-$26.4M	–	27
2021 Q4	$26.4M	Buy	177,648 +30,782	+21%	+$5.51M	2.04%	20
2021 Q3	$27.7M	Buy	146,866 +46,724	+47%	+$8.88M	2.22%	13
2021 Q2	$18.6M	Hold	100,142	–	–	1.72%	14
2021 Q1	$22.8M	Hold	100,142	–	–	1.83%	13
2020 Q4	$21.7M	Buy	+100,142	New	+$16.6M	1.67%	13

Other funds holding STRO

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Frazier Management's STRO Position: Q1 2022 in Review

Frazier Management sold out of Sutro Biopharma (STRO) in Q1 2022, closing a stake of 177,648 shares — an estimated $26.4M sold.

Frazier Management first reported a position in STRO in Q4 2020 and held it in 5 quarters. The position peaked at $27.7M in Q3 2021. 115 funds tracked by Wall St. Rank hold STRO as of Q1 2022.

Frazier Management reported no remaining Sutro Biopharma position as of Q1 2022 after selling out during the quarter.
Frazier Management sold 177,648 Sutro Biopharma shares in Q1 2022, an estimated $26.4M.
Frazier Management first reported a position in Sutro Biopharma in Q4 2020 and held it in 5 quarters.
Frazier Management's Sutro Biopharma position peaked at $27.7M in Q3 2021.
115 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.